CAMP4 THERAPEUTICS CORPORATION CAMP PHARMA
Company Overview
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Why Investors Should Care
Revenue has grown at a 216.1% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.07.
Recent Developments
- Dec 2025 Revenue of $3.50M (+436.5% YoY); net profit $-80.40M.
- Trailing 12 Months Year-on-year growth — revenue +18.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 216.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 216.14% |
| 1 Year: | 18.80% |
Stock Price Performance
| 1 Year: | +201.37% |
| 6 Months: | -29.88% |
| 3 Months: | +7.58% |
| 1 Month: | +3.77% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)53.31 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 216.1% over 5 years.
CONS
- Trading 38.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CAMP CAMP4 THERAPEUTICS CORPORATION PHARMA | 4.40 | -1.90 | $276.11M | 0.00% | -51.38% | - | 216.14% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 0 | 0 | 0 | 858.00K | 1.50M | 795.00K | 348.00K | 1.29M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | 13.96M | 14.53M | 13.95M | 13.12M | 14.37M |
| Operating Income | - | - | -12.34M | -12.88M | -12.66M | -13.52M | -13.10M | -13.03M | -13.16M | -12.78M | -13.07M |
| EBITDA | - | - | - | - | - | - | -12.68M | -12.60M | -12.74M | -12.40M | -12.55M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | -12.43M | -12.59M | -15.10M | -40.28M | -18.33M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -12.51M | -12.10M | -11.70M | -12.46M | -12.57M | -13.48M | -12.43M | -12.59M | -15.10M | -40.28M | -18.33M |
| Diluted EPS | - | - | -29.21 | -26.57 | -26.00 | -24.19 | -0.62 | -0.62 | -0.55 | - | -0.32 |
| R&D Expense | - | - | 9.82M | 9.74M | 9.39M | 9.70M | 10.15M | 10.34M | 9.36M | - | 10.16M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 350.00K | 652.00K | 3.50M |
| Operating Income | -51.88M | -53.09M | -52.55M |
| Net Income | -49.29M | -51.79M | -80.40M |
| Diluted EPS | -124.80 | -11.04 | -2.65 |
| R&D Expense | 40.62M | 38.82M | 38.20M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | - | 54.95M | 78.31M | 117.81M |
| Total Equity | -77.53M | -123.73M | 63.14M | 47.70M |
| Cash & Equivalents | - | 38.38M | 64.04M | 109.52M |
| Total Liabilities | - | 16.53M | 15.16M | 70.10M |
| Current Liabilities | - | 7.81M | 9.60M | 15.51M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -44.16M | -45.56M | -29.55M |
| Investing Cash Flow | -678.00K | -441.00K | -243.00K |
| Financing Cash Flow | 301.00K | 71.66M | 75.89M |
| Capital Expenditure | -678.00K | -441.00K | -279.00K |
| Free Cash Flow | -44.83M | -46.00M | -29.83M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | -14,822.6% | -8,142.3% | -1,502.4% |
| Net Margin % | -14,083.1% | -7,943.4% | -2,298.5% |
| ROE % | 39.8% | -82.0% | -168.5% |
| ROCE % | -110.1% | -77.3% | -51.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Jupiter Topco LLC | 10.05% | 6.31M | $26.74M |
| 2 | 5AM Venture Management, LLC | 9.35% | 5.87M | $24.88M |
| 3 | FMR, LLC | 7.82% | 4.90M | $20.79M |
| 4 | Vivo Capital, LLC | 6.77% | 4.25M | $18.01M |
| 5 | Balyasny Asset Management LP | 4.10% | 2.58M | $10.92M |
| 6 | a16z Capital Management, L.L.C. | 3.39% | 2.13M | $9.01M |
| 7 | Adage Capital Partners GP L.L.C. | 3.12% | 1.96M | $8.31M |
| 8 | Trails Edge Capital Partners, LP | 3.08% | 1.93M | $8.20M |
| 9 | Blackrock Inc. | 2.62% | 1.64M | $6.97M |
| 10 | Vanguard Capital Management LLC | 2.44% | 1.53M | $6.50M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CAMP
A potential treatment for a genetic disorder is expected to enter human testing late in 2026. CAMP4 will discuss it Sept. 28. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxOSXBDN0pJcF8zY19VZW9mTTNoTlZ6S0RxbjhYTktGdjFIYlZJY3NKVHBGcXVReVJPYVhIUHQwOVFOR29ITHo5U0RZbS11VkZpUUE5Z3pINC03Y0RYTXV0c2kzajRVT1AyYVVfQkpRcXlXdVVKNURQVTdDZUVDWHRTS1JDeXJJbHZlTEhLMU…
$CAMP stock is up 14% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPR0drcmR1ZlFuTS1pNWdSZWVGRkZoNnRMd0lOU1diTVhGUU92QW9XVU1tRUtxck5UcWlMX0U5aHBleS1fNXMwU0N2djJIcXRLRTViU01QSUZLS2JIbzRwQi1jQ282aTg0TUJmaFh1d3ZEbk1GemctU3l2LXp1UnY4RGpRYWNTR1A1ZFNRU3…
Stock report | Who are Santana Moss' standouts in Commanders camp? - Washington Commanders
<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxQZG15R0dSaGFFR1dCSkZpU3BuQ2Y4NFJVQmR3cy0wdkE5X2ZfcmZ5ZXBVRlMwcl9PUGFtWU1YUUF1aG94a3lEUzJSTkt6XzdwMktUajE1UE52NExfWnRNTDAweGdHVGV6elJ0d0J5OFpHTklfYmZOX05paWhHd0s0eGNaVHk5WVE?oc=5" …
Stock up, stock down after three weeks of 2026 Eagles training camp - PhillyVoice
<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxPbERacGFsTVZxbXc2T2ZlYlI2Ri1tMDhRY0tQN1lYMGZkRG4xMlpXY1Utdkotc1d6MVcwZl93Ny14MzZNX2NYXzI0VmkwdVhVUFAzWVREajFGVWg2a04tdkhqUkl3Y3lkS2xXMGhYOE5QYVl2MDBkZ1hwOXMxeUJXN3NUTWJUMjBCOWhCSV…
Patriots training camp stock report: Five up, five down from Week 4 - Boston Herald
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxNOFNMeU5oa1BMQkxtb2hqY3FURkVtcW9sRzg4ZTBPRXlVVTlaQnJ5Y0Y4NUNTYnM3dVlpckg3TTFvS25lSm9QQWVMRF9TRDJ5WXFHb1ljWnVXRmdYdHlpNlhoR0RsNWtOSVRzU0syMUpiRFVWZWJDUkw4MnVxaGthVXFYZ2ItaHAwZlZkdW…
AFC West Roundup: Taking stock of the division before training camp - Raiders.com
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxQSWxtR2xVLWs0Tl9MT0NUcWxaVlMxd3ZONkZHUXI3VFllS0xHLU9BWkNITGpEbjZMZ1ZaSW81bUZqLVNidlAzTFlHRVlNckhjRmlBdlZkRUdBeVFJeUpWQVBDM1p1MWsxUkJ1S1FLdGZNNzVnZnVuRWdJTzE0SUJDSmo2MG1Fb1prM1lndk…
CAMP — Frequently Asked Questions
What is the current share price of CAMP4 THERAPEUTICS CORPORATION (CAMP)?
As of 2026-09-19 21:16 PDT, CAMP4 THERAPEUTICS CORPORATION (CAMP) trades at $4.40 on NasdaqGM. Its 52-week range is $1.41 to $7.13.
What is the market capitalisation of CAMP?
CAMP4 THERAPEUTICS CORPORATION (CAMP) has a market capitalisation of $276.11M on NasdaqGM.
What is the P/E ratio of CAMP?
CAMP trades at a trailing price-to-earnings (P/E) ratio of -1.90. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -333.08.
Is CAMP a good stock to buy?
This page provides a data-driven analysis of CAMP4 THERAPEUTICS CORPORATION (CAMP), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.